888739-48-8

Basic information

• Product Name: ethyl 3-{1-[2-chloro-4-(trifluoromethyl)benzyl]-3-isopropoxy-1H-pyrazol-5-yl}propanoate
• Synonyms: ethyl 3-{1-[2-chloro-4-(trifluoromethyl)benzyl]-3-isopropoxy-1H-pyrazol-5-yl}propanoate
• CAS NO: 888739-48-8
• Molecular Weight: 418.843
• Mol File: 888739-48-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 3-{1-[2-chloro-4-(trifluoromethyl)benzyl]-3-isopropoxy-1H-pyrazol-5-yl}propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-{1-[2-chloro-4-(trifluoromethyl)benzyl]-3-isopropoxy-1H-pyrazol-5-yl}propanoate(888739-48-8)
• EPA Substance Registry System: ethyl 3-{1-[2-chloro-4-(trifluoromethyl)benzyl]-3-isopropoxy-1H-pyrazol-5-yl}propanoate(888739-48-8)

Safety Data

• Hazardous Substances Data: 888739-48-8(Hazardous Substances Data)

Upstream product

• 279252-26-5 1-(bromomethyl)-2-chloro-4-(trifluoromethyl)benzene 
• 888738-50-9 methyl 3-isopropoxy-1H-pyrazole-5-carboxylate 
• 888738-72-5 methyl 1-benzyl-3-isopropoxy-1H-pyrazole-5-carboxylate 
• 888738-74-7 (1-benzyl-3-isopropoxy-1H-pyrazol-5-yl)methanol 
• 888738-75-8 1-benzyl-3-isopropoxy-1H-pyrazole-5-carbaldehyde 
• 888738-76-9 ethyl (E)-3-(1-benzyl-3-isopropoxy-1H-pyrazol-5-yl)propenoate 
• 888738-15-6 ethyl 3-(3-isopropoxy-1H-pyrazol-5-yl)propanoate 
• 24096-63-7 2-chloro-1-(chloromethyl)-4-(trifluoromethyl)benzene 

Downstream Products

• 926300-17-6 3-{1-[2-chloro-4-(trifluoromethyl)benzyl]-3-isopropoxy-1H-pyrazol-5-yl}-N-(pentylsulfonyl)propanamide 

Relevant articles and documents

A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: Design and synthesis of benzylpyrazole acylsulfonamides

Herein, we describe the design, synthesis, and structure-activity relationships of novel benzylpyrazole acylsulfonamides as non-thiazolidinedione (TZD), non-carboxylic-acid-based peroxisome proliferator-activated receptor (PPAR) γ agonists. Docking model analysis of in-house weak agonist 2 bound to the reported PPARγ ligand binding domain suggested that modification of the carboxylic acid of 2 would help strengthen the interaction of 2 with the TZD pocket and afford non-carboxylic-acid-based agonists. In this study, we used an acylsulfonamide group as the ring-opening analog of TZD as an isosteric replacement of carboxylic acid moiety of 2; further, preliminary modification of the terminal alkyl chain on the sulfonyl group gave the lead compound 3c. Subsequent optimization of the resulting compound gave the potent agonists 25c, 30b, and 30c with high metabolic stability and significant antidiabetic activity. Further, we have described the difference in binding mode of the carboxylic-acid-based agonist 1 and acylsulfonamide 3d.

ARYLALKANOIC ACID DERIVATIVE

A compound represented by the formula (I): wherein Ar is an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1 and Z2 are each a bond, O, S, -CO-, -CS-, - CR3 (OR4) -, -NR5-, -SO-, -SO2-, -CONR6- or -NR6CO- (wherein R3, R4, R5 and R6 are as defined in the specification); Xb and Yb are each a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group; ring A is an optionally further substituted aromatic ring, provided that the ring should not be benzimidazole; n is an integer of 1 to 8; ring B is an optionally further substituted aromatic ring, provided that the ring should not be oxazole; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; and R2 is -OR8 or -NR9R10 (wherein R8, R9 and R10 are as defined in the specification) or a salt thereof, is useful as an agent for the prophylaxis or treatment of diabetes and the like.